ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / BYSI / dividends
BCTX (40) ABVC (32) CPHI (35) CELU (26) ⌘ Pro Terminal →

BeyondSpring Inc. (BYSI) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.64 +24.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.67

BeyondSpring Inc. (BYSI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $26.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BYSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.64 (+24.60% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BYSI ranks #546 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BYSI compare to BCTX and ABVC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BYSI?
▼

Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.67 (+4.24%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (4)Whales (8)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$3 Bull$1 Base$0 Bear
📬 FREE BYSI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BYSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY BYSI SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$0.61-14.8% Next Q
Q2 (-2Q)
32
Grade E$0.52-11.5% Next Q
Q3 (-1Q)
34
Grade E$0.46+39.1% Next Q
Current
37
Grade D-$0.64-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BYSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BYSI currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.67) forces dealer call-delta covering toward $2.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BYSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BYSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYSI)

  • ✓Walkthrough of BYSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BYSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.62%▼ DESCENDING CHANNEL
2026-11-03O $0.51H $0.64L $0.51C $0.64VOL 219.1K
RES: $0.96SUP: $0.39SMA50: $0.65SMA200: $1.26
$2.03$1.59$1.15$0.72$0.28RES $0.96SUP $0.39$0.642026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BYSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BYSI Butterfly Map → + Track BYSI →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BYSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BYSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BYSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYSI)

Health Care Rank #546 of 1016 ⚔️ BCTX vs BYSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BYSI vs. BCTX, ABVC, CPHI, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BeyondSpring Inc. (BYSI) ranks #546 by composite RQD confidence (37/100, grade D-) and #812 by equity capitalization ($26.5M). Within this direct 5-issuer industry benchmark cohort, BYSI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BYSI at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BYSI ACTIVE
BeyondSpring Inc.
D- 37/100 — — -35.0% +24.60% $26.5M Benchmark Subject
BCTX
BriaCell Therapeutics Corp.
D- 40/100 — — — -8.16% $26.5M /bctx-vs-bysi →
ABVC
ABVC BioPharma Inc.
E 32/100 — — -35.0% -3.85% $26.7M /abvc-vs-bysi →
CPHI
China Pharma Holdings Inc.
D- 35/100 — -3.2% -11.4% -3.86% $26.9M /cphi-vs-bysi →
CELU
Celularity Inc. (Class A)
E 26/100 — 24.4% -35.0% -5.79% $26.0M /celu-vs-bysi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001677940

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BeyondSpring Inc. (BYSI) reported GAAP revenue of $25.0M (+2.2% vs. FY2024 revenue of $24.5M , and -40.7% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of -$19.8M, and free cash flow of -$19.8M (-18.9% YoY). On the balance sheet, BYSI closed FY2025 with $25.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $25.0M -$1.0M -$19.8M -$19.8M $25.9M —
FY2024 (FY) 2024-12-31 $24.5M -$11.1M -$16.4M -$16.7M $34.3M —
FY2023 (FY) 2023-12-31 $42.2M -$21.0M -$16.5M -$16.5M — —

3. BYSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.64 (+24.60% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BYSI ranks #546 in composite RQD confidence.

How does BYSI compare to BCTX and ABVC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BYSI?

Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BYSI trading relative to its 50-day, 200-day, and 52-week technical levels?

BYSI last traded at $0.64 (+24.60% on volume of 219,060 shares), positioning the stock -1.54% below its 50-day simple moving average ($0.65) and -49.21% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.42 to $2.44, BYSI sits at the 10.9% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.72).

Direct Sub-Reports: BYSI RQD Cockpit BYSI 12M Forecast BYSI Earnings & Move BYSI Dividends & DRIP BYSI Insiders & 13F BYSI Whale Options BYSI Profit Sankey BYSI News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BYSI — BeyondSpring Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:49:43Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BYSI scores 34 out of 100, earning an E grade and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

  • Fundamental Cash Engine: 4 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. Per the SEC financials, FY 2025 free cash flow was $-19.8M against operating income of $-8.9M.
  • Whale / 13F Flow: 6 / 20. The RQD rating describes this pillar as covering institutional accumulation and options positioning. The holders section contains no data, so the score cannot be traced to specific filings in the source data. A low score here suggests limited institutional support in the sourced record.
  • Insider Conviction: 5 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow.
  • Macro Regime Fit: 9 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is factored in. A beta of 1.0 indicates market-equivalent sensitivity; the score reflects that the stock does not offer a clear macro-regime tailwind per the rating methodology.
  • Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski score of 2 out of 9 is a weak reading on fundamental quality, and the Altman Z of 2.5 sits in the zone the rating treats as a meaningful but not extreme distress signal.

Upside drivers, as framed by the data, would require a turn from negative ROIC and negative operating income toward positive cash generation. Valuation tradeoffs are severe: the market capitalization is $21.2M against cash of $7.8M and FCF of $-19.8M, so the equity is priced on expectations the sourced financials do not yet demonstrate. The stock's price of 0.52 sits within a 52-week range of $0.42 - $2.44, meaning it trades near the lower end of its recent band.

Business

BeyondSpring Inc. is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Per the SEC financials, reported revenue is — in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the sourced periods. Product offerings, customers, and revenue model details are —

Recent Catalysts & News Wire Analysis

The news wire contains five items, all tagged to BYSI and all carrying a YELLOW light and a MARKET WIRE impact label. The items are generic market-report summaries: a Moomoo options chain page; a StockInvest.us price forecast; a Stock Titan report on a passive stake held through two funds by one manager; and two items attributed to a Diagonal Spread Trade and a Golden Cross reading, both describing the stock slipping 3.90% to $0.56. Risk watch items include the sub-$1 price and the ongoing negative operating income. Per the Butterfly Supply-Chain Graph, the supply_chain field is NONE, there are no butterfly links, and there are no proprietary signals. The catalyst content does not identify specific clinical, regulatory, or commercial events; those details are —

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies: — Sector correlations beyond the Health Care classification: — Second-order bottlenecks: —

Open Questions

  • What specific clinical, regulatory, or product milestones drive the company's path to revenue, given zero reported revenue across FY 2023–FY 2025?
  • What is the debt position, since the financials list debt as N/A while the RQD rating cites Debt/Equity of 0.5?
  • How does the company fund its negative free cash flow, and what is the runway implied by the reported cash of $7.8M?
  • What is the source and nature of the 13F-related passive stake referenced in the news wire, and who are the holders?
  • Why does the net loss narrow from $-11.1M in FY 2024 to $-1.0M in FY 2025 while operating income remains near $-8.9M?

BYSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BeyondSpring Inc. (BYSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BYSI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BYSI Bull vs. Bear Conversation Board — What's Your Call at $0.64?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BYSI 🐻 67% BEARISH CONVICTION
1. Pick Your Side on BYSI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.46 (-11.5%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BYSI (E • RQD 34/100) a Buy at $0.52?

Welcome to the BYSI (BeyondSpring Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.44 (-15.4%)
Spot @ $0.52

Pump the brakes on BYSI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BYSI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless BeyondSpring Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.64 (+23.1%)
Spot @ $0.52

BYSI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BYSI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.52 (52-wk range $0.42 - $2.44), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%